Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–60.

Article  CAS  PubMed  Google Scholar 

Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–93.

Article  CAS  PubMed  Google Scholar 

Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16.

Article  CAS  PubMed  Google Scholar 

Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571–92.

Article  PubMed  Google Scholar 

Bibeau K, Pandya AG, Ezzedine K, Jones H, Gao J, Lindley A, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan, and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32.

Article  PubMed  PubMed Central  Google Scholar 

Eleftheriadou V, Atkar R, Batchelor J, McDonald B, Novakovic L, Patel JV, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18–29.

Article  CAS  PubMed  Google Scholar 

Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110–20.

Article  CAS  PubMed  Google Scholar 

Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623–33.

Article  PubMed  Google Scholar 

Rashighi M, Harris JE. Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med. 2015;3(21):343.

PubMed  PubMed Central  Google Scholar 

Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3): e24137.

PubMed  PubMed Central  Google Scholar 

Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109–17.

Article  PubMed  PubMed Central  Google Scholar 

Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield L, Leung DY, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863–72.

Article  CAS  PubMed  Google Scholar 

Opzelura™ (ruxolitinib cream). Full Prescribing Information. Wilmington: Incyte Corporation; 2023.

Google Scholar 

Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2023;88(5):1008–16.

Article  CAS  PubMed  Google Scholar 

Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387:1445–55.

Article  CAS  PubMed  Google Scholar 

Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance: reporting requirements throughout a product’s lifecycle. Ther Adv Drug Saf. 2022;13:20420986221125006.

Article  PubMed  PubMed Central  Google Scholar 

US FDA. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment: Guidance for Industry. 2005. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment. Accessed 12 Jun 2023.

Delong C, Preuss CV. Black box warning. StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.

US FDA. Prescribing Information Resources: For Industry. 2023. https://www.fda.gov/drugs/fdas-labeling-resources-human-prescription-drugs/prescribing-information-resources#:~:text=What%20is%20the%20Prescribing%20Information,the%20labeled%20conditions%20of%20use. Accessed 8 Jun 2023.

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26.

Article  CAS  PubMed  Google Scholar 

Kragstrup TW, Glintborg B, Svensson AL, McMaster C, Robinson PC, Deleuran B, et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8(1): e002236.

Article  PubMed  PubMed Central  Google Scholar 

US FDA. Postmarketing Adverse Event Reporting Compliance Program. https://www.fda.gov/drugs/surveillance/postmarketing-adverse-event-reporting-compliance-program. Accessed 29 Sep 2023.

US FDA. What Is a Serious Adverse Event? 2023. https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event. Accessed 9 Jun 2023.

European Medicines Agency. Inclusion/exclusion criteria for the "Important Medical Events" list. European Medicines Agency. 2021. https://www.ema.europa.eu/en/documents/other/inclusion-exclusion-criteria-important-medical-events-list-meddra_en.pdf. Accessed 29 Sep 2023.

Brabete AC, Greaves L, Maximos M, Huber E, Li A, Le ML. A sex- and gender-based analysis of adverse drug reactions: a scoping review of pharmacovigilance databases. Pharmaceuticals (Basel). 2022;15(3):298.

Article  PubMed  Google Scholar 

Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E, et al. Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies. Am J Clin Dermatol. 2021;22(4):555–66.

Article  PubMed  PubMed Central  Google Scholar 

Opzelura™ (ruxolitinib cream). Summary of Product Characteristics. Amsterdam: Incyte Biosciences Distribution B.V.; 2023.

Google Scholar 

Jensen AO, Svaerke C, Körmendiné Farkas D, Olesen AB, Kragballe K, Sørensen HT. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977–2006). Am J Clin Dermatol. 2012;13(1):29–36.

Article  PubMed  Google Scholar 

Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. Epidemiological trends in skin cancer. Dermatol Pract Concept. 2017;7(2):1–6.

Article  PubMed  PubMed Central  Google Scholar 

Prepoudis A, Koechlin L, Nestelberger T, Boeddinghaus J, Lopez-Ayala P, Wussler D, et al. Incidence, clinical presentation, management, and outcome of acute pericarditis and myopericarditis. Eur Heart J Acute Cardiovasc Care. 2022;11(2):137–47.

Article  PubMed  Google Scholar 

Weycker D, Hanau A, Hatfield M, Wu H, Sharma A, Bensink ME, et al. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. J Med Econ. 2020;23(2):184–92.

Article  PubMed  Google Scholar 

Institute of Medicine of the National Academies. Challenges for the FDA: The Future of Drug Safety. Workshop Summary. Washington, DC: Institute of Medicine Forum on Drug Discovery, Development, and Translation; 2007.

Kavitha D. Adverse drug reaction (ADR) monitoring and pharmacovigilance. J Pharm Res Health Care. 2010;2(1):127–34.

Google Scholar